Free Trial

Praxis Precision Medicines (NASDAQ:PRAX) Given New $568.00 Price Target at Robert W. Baird

Praxis Precision Medicines logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Robert W. Baird raised its price target on Praxis Precision Medicines from $514 to $568 and maintained an “outperform” rating, implying 73.1% upside from the prior close.
  • Analyst views are mixed, though the consensus is “Moderate Buy” with a $634.53 target; ratings include three Strong Buys, 16 Buys, one Hold and two Sells.
  • Praxis reported a quarterly loss of $3.23 per share, narrower than analysts’ expected loss of $3.54 per share.
  • MarketBeat previews the top five stocks to own by December 1st.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) had its price objective upped by research analysts at Robert W. Baird from $514.00 to $568.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Robert W. Baird's price objective suggests a potential upside of 73.10% from the stock's previous close.

Several other equities research analysts also recently commented on PRAX. Raymond James Financial reaffirmed a "strong-buy" rating and set a $945.00 price objective on shares of Praxis Precision Medicines in a report on Monday, August 17th. Wall Street Zen downgraded shares of Praxis Precision Medicines from a "hold" rating to a "sell" rating in a research note on Saturday, October 17th. BTIG Research reiterated a "buy" rating and issued a $826.00 target price on shares of Praxis Precision Medicines in a research note on Monday, November 9th. The Goldman Sachs Group reissued a "buy" rating and issued a $575.00 price target (up from $470.00) on shares of Praxis Precision Medicines in a research report on Friday, August 21st. Finally, Royal Bank Of Canada upped their price target on shares of Praxis Precision Medicines from $462.00 to $478.00 and gave the company an "outperform" rating in a research note on Tuesday, November 10th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Praxis Precision Medicines has a consensus rating of "Moderate Buy" and a consensus price target of $634.53.

Check Out Our Latest Stock Analysis on PRAX

Praxis Precision Medicines Price Performance

Shares of NASDAQ PRAX opened at $328.13 on Monday. Praxis Precision Medicines has a one year low of $160.11 and a one year high of $392.70. The business's fifty day moving average price is $289.90 and its 200-day moving average price is $314.38. The stock has a market capitalization of $9.17 billion, a PE ratio of -25.64 and a beta of 2.85.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($3.23) earnings per share for the quarter, topping the consensus estimate of ($3.54) by $0.31. As a group, equities analysts expect that Praxis Precision Medicines will post -13.93 EPS for the current fiscal year.

Institutional Trading of Praxis Precision Medicines

A number of institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its holdings in shares of Praxis Precision Medicines by 6.8% in the first quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company's stock worth $1,113,514,000 after buying an additional 218,777 shares in the last quarter. Perceptive Advisors LLC boosted its position in shares of Praxis Precision Medicines by 2.0% in the first quarter. Perceptive Advisors LLC now owns 2,035,986 shares of the company's stock valued at $655,974,000 after acquiring an additional 40,000 shares during the period. Bank of America Corp DE grew its stake in Praxis Precision Medicines by 2.3% during the first quarter. Bank of America Corp DE now owns 534,604 shares of the company's stock valued at $172,244,000 after acquiring an additional 11,841 shares in the last quarter. Vivo Capital LLC grew its stake in Praxis Precision Medicines by 3.0% during the first quarter. Vivo Capital LLC now owns 338,895 shares of the company's stock valued at $109,189,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in Praxis Precision Medicines by 61.7% during the third quarter. Marshall Wace LLP now owns 221,602 shares of the company's stock valued at $64,537,000 after acquiring an additional 84,594 shares in the last quarter. Hedge funds and other institutional investors own 67.84% of the company's stock.

About Praxis Precision Medicines

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Featured Articles

Analyst Recommendations for Praxis Precision Medicines (NASDAQ:PRAX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Praxis Precision Medicines Right Now?

Before you consider Praxis Precision Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.

While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines